OVOCA BIO PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.01 EUR | -.--% |
|
-.--% | -.--% |
| 2021 | Ovoca Bio : Enrolls First Patient in Phase 2 Trial for Hypoactive Sexual Desire Disorder Treatment | MT |
Business Summary
At the end of 2022, the Group had a product in phase III clinical development (Orenetide).
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 88,458,806 | 42,053,448 ( 47.54 %) | 6,895,000 ( 7.795 %) | 47.54 % |
Company contact information
Group companies
| Name | Category and Sector |
|---|---|
Silver Star Ltd. (Bermuda)
|
Miscellaneous
|
Sector
Sales per Business
Sales per region
| 1st Jan change | Capi. | |
|---|---|---|
| +5.33% | 111B | |
| +12.11% | 106B | |
| -12.56% | 22.24B | |
| -3.32% | 21.25B | |
| -5.89% | 18.97B | |
| -35.21% | 18.52B | |
| -10.86% | 16.81B | |
| +37.57% | 12.54B | |
| -26.24% | 8.09B |
- Stock Market
- Equities
- OVXA Stock
- OVXA Stock
- Company Ovoca Bio plc
